
The FDA approved use of tissue plasminogen activator (tPA) for stroke in 1996, but it took another 10 years for the Centers for Medicare and Medicaid Services to offer reimbursement. The agency's decision is part of a larger trend that recognizes the value of preventive care and treatment compared with the cost of longer hospital stays.























